Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer patients
Wednesday, December 10, 2014 - 16:31
in Health & Medicine
A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer.